Published in Vaccine Weekly, June 7th, 2000
In a trial in 14 patients conducted at the Johns Hopkins Oncology Center, three of eight patients receiving the two highest doses of the vaccine are alive and free of disease for more than two years following treatment, while the six patients receiving the two lowest doses have relapsed. Additionally, all three of the patients with prolonged disease-free survival have biopsy-proven vaccine-induced antitumor immunity, a finding...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly